Zanoterone

CAS No. 107000-34-0

Zanoterone( —— )

Catalog No. M36136 CAS No. 107000-34-0

Zanoterone is an AR antagonist (androgen receptor).Zanoterone has antitumor activity for the treatment of genitourinary disorders and oncological disorders and may be used in the study of prostate cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 290 Get Quote
5MG 456 Get Quote
10MG 653 Get Quote
25MG 994 Get Quote
50MG 1362 Get Quote
100MG 1791 Get Quote
500MG 3528 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Zanoterone
  • Note
    Research use only, not for human use.
  • Brief Description
    Zanoterone is an AR antagonist (androgen receptor).Zanoterone has antitumor activity for the treatment of genitourinary disorders and oncological disorders and may be used in the study of prostate cancer.
  • Description
    Zanoterone is an AR antagonist (androgen receptor).Zanoterone has antitumor activity for the treatment of genitourinary disorders and oncological disorders and may be used in the study of prostate cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Androgen Receptor (AR)
  • Recptor
    Androgen Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    107000-34-0
  • Formula Weight
    416.58
  • Molecular Formula
    C23H32N2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)[C@@](C#C)(O)CC4)[H])(CC[C@]1(CC=5C(C2)=CN(S(C)(=O)=O)N5)[H])[H])[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • JNJ63576253

    JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).

  • AZD3514

    AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression.Phase 1.

  • DL-α-Tocopherol

    Antioxidant.